Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 16/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.77 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.60 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.60 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845955 | 0.90 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL30730005 | 0.89 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL8359220 | 0.89 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL2848785 | 0.88 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL30255515 | 0.87 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL29712005 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL29518128 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL7721750 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL13061682 | 0.87 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL16063039 | 0.86 | GABRG2 (0.83) | GABRG2GABRB3GABRA3GABRA5GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4129297-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM Research Foundation, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3439665-B1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RES FOUNDATION INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2021-10-07 | — | — | US | disclosed |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEARCH FOUNDATION, INC. | 2020-06-11 | — | — | US | disclosed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180065967-A1 | GABAERGIC LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2018-03-08 | — | — | US | disclosed |
| WO-2017161370-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEACH FOUNDATION, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7119196-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-29 | — | — | US | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | GABRE, GABRA6, GABRA5 | GABRG2 21/4885GABRB3 14/4885GABRA3 11/4885 |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRG2 25/4885GABRB3 10/4885GABRA3 5/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRG2 14/4885GABRB3 8/4885GABRA3 1/4885 |
| US-20180065967-A1 | GABAERGIC LIGANDS AND THEIR USES | GABRA3, GABRB3, GABRA2 | GABRG2 11/4885GABRB3 2/4885GABRA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.